| P2093 | author name string | L Trodella | |
| | R Coppola | |
| | D Santini | |
| | B Vincenzi | |
| | G Tonini | |
| | B Beomonte Zobel | |
| | C Rabitti | |
| P2860 | cites work | Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment | Q44820379 |
| | Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. | Q46641340 |
| | A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. | Q53553125 |
| | The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. | Q54242652 |
| | Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67 | Q67581898 |
| | CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR | Q73409052 |
| | Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples | Q24569561 |
| | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 |
| | Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 |
| | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 |
| | Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer | Q33810043 |
| | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 |
| | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 |
| | New chemotherapy approaches in colorectal cancer | Q34295174 |
| | Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts | Q34523090 |
| | Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 |
| | Why the epidermal growth factor receptor? The rationale for cancer therapy | Q34803451 |
| | Epithelial growth factor receptor interacting agents | Q35038746 |
| | Critical evaluation of current treatments in metastatic colorectal cancer | Q36093979 |
| | Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? | Q36140967 |
| | Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? | Q36211421 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| | irinotecan | Q412197 |
| | cetuximab | Q420296 |
| | colorectal carcinoma | Q25493920 |
| | phase II clinical trial | Q42824440 |
| P304 | page(s) | 792-797 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial | |
| P478 | volume | 94 | |